Drug safety advice
-
Interferon-beta: risk of thrombotic microangiopathy and risk of nephrotic syndrome
There have been reports of thrombotic microangiopathy and nephrotic syndrome linked to interferon beta treatment. Be vigilant for early signs or symptoms of these conditions (see below) and treat these conditions promptly if they occur.
-
From October 2014 Dexamethasone 4 mg/ml injection (Organon Laboratories Limited) will be replaced with a new formulation called Dexamethasone 3.8 mg/ml solution for injection (Aspen Pharma Trading Limited).
Stop Press
-
In clinical trials, serious cardiac side effects were observed more frequently with basiliximab than with other induction agents.
Other information from the MHRA
-
Drugs and driving: clarification for Wales, Scotland, and Northern Ireland
- This new offence will be enforceable in England, Wales, and Scotland but not Northern Ireland where the introduction of a similar offence is under consideration.